Drugs / Xolatryp
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07362446 | Jul 2026 → Jun 2027 expected | ST-elevation myocardial infarction | Nyrada Pty Ltd | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-30 | Nyrada Pty Ltd | Nyrada US Patent for Xolatryp Granted nyrada.com ↗ |
| 2025-05-23 | Nyrada Pty Ltd | Lead Drug Candidate Renamed to Xolatryp nyrada.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xolatryp | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07362446 ↗ |
| Route | Intravenous | “Xolatryp administered as a continuous intravenous (i.v) infusion for 6 hours.” NCT07362446 ↗ |